|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
123,030,000 |
Market
Cap: |
18.44(B) |
Last
Volume: |
512,792 |
Avg
Vol: |
724,527 |
52
Week Range: |
$143.31 - $211.65 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 824 |
Guru Rank Value : 0.5 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
45,264 |
76,855 |
102,504 |
247,093 |
Total Sell Value |
$6,835,665 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
Total People Sold |
6 |
7 |
8 |
9 |
Total Sell Transactions |
10 |
12 |
18 |
35 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fitzgerald Kevin Joseph |
CSO & EVP, Head of ResearchOff |
|
2024-03-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
537 |
|
2% |
|
Fitzgerald Kevin Joseph |
CSO & EVP, Head of ResearchOff |
|
2024-03-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,881 |
|
2% |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,741 |
27,219 |
|
- |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,751 |
13,417 |
|
- |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,754 |
71,882 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,751 |
9,987 |
|
- |
|
Sharp Philip A |
Director |
|
2024-02-29 |
4 |
AS |
$150.60 |
$4,540,071 |
D/D |
(30,000) |
0 |
|
-0% |
|
Sharp Philip A |
Director |
|
2024-02-29 |
4 |
OE |
$59.25 |
$1,777,500 |
D/D |
30,000 |
30,000 |
|
- |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2024-02-28 |
4 |
S |
$154.54 |
$89,145 |
D/D |
(574) |
8,666 |
|
3% |
|
Franchini Indrani Lall |
EVP, CLO & Secretary |
|
2024-02-28 |
4 |
S |
$154.54 |
$51,095 |
D/D |
(329) |
4,133 |
|
3% |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2024-02-28 |
4 |
S |
$154.54 |
$77,805 |
D/D |
(501) |
5,236 |
|
3% |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2024-02-28 |
4 |
S |
$154.54 |
$455,357 |
D/D |
(2,932) |
48,128 |
|
3% |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2024-02-28 |
4 |
S |
$154.54 |
$89,145 |
D/D |
(574) |
19,478 |
|
3% |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2024-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,908 |
9,240 |
|
- |
|
Franchini Indrani Lall |
EVP, CLO & Secretary |
|
2024-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
878 |
4,462 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2024-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,667 |
5,737 |
|
- |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2024-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,921 |
51,060 |
|
- |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2024-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,908 |
20,052 |
|
- |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2024-02-16 |
4 |
S |
$147.50 |
$149,099 |
D/D |
(1,007) |
18,144 |
|
-2% |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2024-02-16 |
4 |
S |
$147.50 |
$193,666 |
D/D |
(1,308) |
7,332 |
|
-2% |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2024-02-16 |
4 |
S |
$147.50 |
$149,397 |
D/D |
(1,009) |
4,070 |
|
-2% |
|
Greenstreet Yvonne |
Chief Executive Officer |
|
2024-02-16 |
4 |
S |
$147.50 |
$1,040,885 |
D/D |
(7,030) |
45,139 |
|
-2% |
|
Poulton Jeffrey V. |
EVP, Chief Financial Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,278 |
19,151 |
|
- |
|
Garg Pushkal |
CMO & EVP Dev & Med Affairs |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,295 |
8,640 |
|
- |
|
Tanguler Tolga |
EVP, Chief Commercial Officer |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,278 |
5,079 |
|
- |
|
746 Records found
|
|
Page 1 of 30 |
|
|